Adjuvant therapy with toceranib for hepatocellular carcinoma and cholangiocarcinoma in a Pomeranian

A 10-year-old spayed female Pomeranian dog was referred for hepatic mass evaluation. Blood tests revealed mildly elevated alkaline phosphatase activities. Computed tomography a with multiple nodules on the right medial lobe adjacent to caudal vena cava; histopathology confirmed mixed hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of incomplete resection, adjuvant therapy recommended. As tumour cells showed PDGFR-α, c-Kit, FGFR1 overexpression, anticancer effect tyrosine kinase inhibitors evaluated cells; toceranib most effective administered starting an extra-labelled dose. The remained stable 2.3 years mild adverse effects. To our knowledge, this is first successful clinical application in HCC-CC.